Korea Joong Myung Cho of Korean biotech success story CrystalGenomics introduces the company’s unique drug discovery platform, key growth factors, highly promising R&D pipeline, and internationalisation plans. We were the first Korean biotech to have independently developed, commercialized, marketed and exported an innovative drug Dr Cho, could you start by…
Taiwan Taiwan Bio Industry Organization Chairman Dr Johnsee Lee outlines the Taiwanese biopharmaceutical industry’s rapid and coordinated response to the COVID-19 crisis and also explains how Quark Biosciences’ diagnostics and precision medicine expertise is aiding this effort. The silver lining of the crisis is that it has provided opportunities for…
Portugal Coimbra Genomics aims to make genetics easier. The company has developed Elsie, a digital platform that helps make better individualized clinical decisions. They have recently been recognized as the ‘second biggest promise in European e–Health’. Bruno Soares shares the Coimbra Genomics story, plans and exciting news for 2018, and how Elsie…
UK Sir John Chisholm, executive chair of Genomics England – a company set up and owned by the UK Department of Health to run the 100,000 Genomes Project, which aims to sequence 100,000 genomes from NHS patients with a rare disease and their families, and patients with cancer – discusses the…
Taiwan Daniel Huang, CEO of Genomics Bioscience, Taiwan’s largest commercial genome sequencing company, and Chairman of Pharmigene, a global leader in the development and manufacturing of genetic tests, documents how he plans to leverage the combined capacity and expertise of these two companies to form strategic alliances with leading pharmaceutical companies…
Taiwan Johnsee Lee, founder, CEO, and president of Personal Genomics and its sister company Quark Biosciences, provides insights into the company’s proprietary Optoelectronic Sequencing (OES) technology, which can perform whole genome sequencing thousand times faster than existing technologies and increase read length twentyfold in comparison to sequencing products currently on the…
biotech Landsteiner is betting on biotech and genomics. The head of new developments and the head of genomic research share their views on the future of the company as well as the importance of embedding new technology in new product developments to better adapt to the changing needs of the Mexican…
commercialization The President of Argenomics highlights the position of his company as the bridge between science and business in Argentina. Could you please provide an historical overview of Argenomics? Several years ago, during my time as an employee of a multinational pharma company, I met a medical doctor and a…
Clinical trials The President & CEO of Vita Genomics talks about the advantages that genomic testing offer both to sick and healthy patients, as well as the opportunities to catalogue the science behind Traditional Chinese Medicine. What is the vision behind Vita Genomics? Vita Genomics was founded in 2001. At the time,…
See our Cookie Privacy Policy Here